The NCAA Division I Council recently voted to remove cannabinoids from their banned drug class for postseason football and NCAA championships.
On June 25, 2024, the National Collegiate Athletics Association (NCAA) Division I Council met and voted to remove cannabinoids from the banded drug class involving NCAA championships and postseason football. This ruling was set to go into effect immediately (1).
Previous NCAA policy stated that (2), “cannabinoids are one of five substances tested for ahead of championships and postseason football games. The NCAA also tests for beta-2 agonists, beta blockers (in rifle), stimulants and narcotics ahead of those events.” If an athlete tests positive for cannabis, it could lead to them receiving a suspension. During the season, schools maintain their own drug testing standards, while the NCAA managed drug testing during the postseason. If a positive test result shows up on a test conducted by the NCAA, a harsher penalty is usually handed down than what the school would have enacted (1).
“The NCAA drug testing program is intended to focus on integrity of competition, and cannabis products do not provide a competitive advantage,” Josh Whitman, Council chair and Illinois athletic director, commented (1). “The council’s focus is on policies centered on student-athlete health and well-being rather than punishment for cannabis use.”
The New York Times reported that back in 2019 (1), three football players in Oklahoma received a six-game suspension because the student athletes had tested positive for cannabis prior to the Peach Bowl College Football Playoff (CFP) semifinal game. As a postseason game, the athletes’ suspensions were continued into the following 2020 season.
In a September 2023 NCAA press release (3), the National Collegiate Athletic Association (NCAA) Committee on Competitive Safeguards and Medical Aspects of Sports (CSMAS) formally announced their recommendation that cannabis should be removed from the organization’s banned substances list for college athletes. The committee also stated that all three of the organization’s governing bodies should “introduce and adopt legislation that would remove cannabinoids from the list of NCAA banned drug classes.”
This recommendation was offered after an extensive study informed by industry and subject matter experts. In December 2022, the NCAA also hosted a Summit on Cannabinoids in College Athletics (4). The consensus opinion formed at that event was that cannabis was not a performance-enhancing drug and that a harm-reduction approach to cannabis would be best implemented at the school level.
With the NCAA Division I Council’s ruling, it will hopefully ignite future changes in sport regulations. The Pew Research Center reported that as of April 2024, 24 stated in the United States (US) have legalized recreational cannabis (5). Although the popularity of cannabis is growing, it still faces various roadblocks stalling it from being an accepted option for both athletes and recreational and medical consumers.
References
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.